| Mucopolysaccharidosis type II: one hundred years of research, diagnosis, and treatment F D’Avanzo, L Rigon, A Zanetti, R Tomanin International journal of molecular sciences 21 (4), 1258, 2020 | 146 | 2020 |
| Targeted polymeric nanoparticles for brain delivery of high molecular weight molecules in lysosomal storage disorders M Salvalaio, L Rigon, D Belletti, F D’Avanzo, F Pederzoli, B Ruozi, ... PloS one 11 (5), e0156452, 2016 | 108 | 2016 |
| Familial temporal lobe epilepsy with psychic auras associated with a novel LGI1 mutation P Striano, G Busolin, L Santulli, E Leonardi, A Coppola, L Vitiello, L Rigon, ... Neurology 76 (13), 1173-1176, 2011 | 62 | 2011 |
| Targeting brain disease in MPSII: preclinical evaluation of IDS-loaded PLGA nanoparticles L Rigon, M Salvalaio, F Pederzoli, E Legnini, JT Duskey, F D’Avanzo, ... International journal of molecular sciences 20 (8), 2014, 2019 | 58 | 2019 |
| Molecular diagnosis of patients affected by mucopolysaccharidosis: a multicenter study A Zanetti, F D’Avanzo, L Rigon, A Rampazzo, D Concolino, R Barone, ... European Journal of Pediatrics 178, 739-753, 2019 | 40 | 2019 |
| Brain RNA-seq profiling of the mucopolysaccharidosis type II mouse model M Salvalaio, F D’Avanzo, L Rigon, A Zanetti, M D’Angelo, G Valle, ... International Journal of Molecular Sciences 18 (5), 1072, 2017 | 40 | 2017 |
| FGF signaling deregulation is associated with early developmental skeletal defects in animal models for mucopolysaccharidosis type II (MPSII) S Bellesso, M Salvalaio, S Lualdi, E Tognon, R Costa, P Braghetta, ... Human molecular genetics 27 (13), 2262-2275, 2018 | 37 | 2018 |
| LGI1 microdeletion in autosomal dominant lateral temporal epilepsy M Fanciulli, L Santulli, L Errichiello, C Barozzi, L Tomasi, L Rigon, ... Neurology 78 (17), 1299-1303, 2012 | 35 | 2012 |
| Circadian transcriptome analysis in human fibroblasts from Hunter syndrome and impact of iduronate-2-sulfatase treatment G Mazzoccoli, R Tomanin, T Mazza, F D’Avanzo, M Salvalaio, L Rigon, ... BMC Medical Genomics 6, 1-20, 2013 | 20 | 2013 |
| Exploiting the Potential of Drosophila Models in Lysosomal Storage Disorders: Pathological Mechanisms and Drug Discovery L Rigon, C De Filippis, B Napoli, R Tomanin, G Orso Biomedicines 9 (3), 268, 2021 | 19 | 2021 |
| Modeling mucopolysaccharidosis type II in the fruit fly by using the RNA interference approach L Rigon, N Kucharowski, F Eckardt, R Bauer Life 10 (11), 263, 2020 | 10 | 2020 |
| Composition and structure of glycosaminoglycans in DBS from 2-3-day-old newborns for the diagnosis of mucopolysaccharidosis F Maccari, F Galeotti, V Mantovani, L Zampini, L Padella, L Rigon, ... Analytical biochemistry 557, 34-41, 2018 | 7 | 2018 |
| Glycosaminoglycan signatures in body fluids of mucopolysaccharidosis type II mouse model under long-term enzyme replacement therapy F Maccari, L Rigon, V Mantovani, F Galeotti, M Salvalaio, F D’Avanzo, ... Journal of Molecular Medicine 100 (8), 1169-1179, 2022 | 5 | 2022 |
| ADAM23, a gene related to LGI1, is not linked to autosomal dominant lateral temporal epilepsy L Rigon, A Vettori, G Busolin, G Egeo, P Pulitano, L Santulli, E Pasini, ... Epilepsy research and treatment 2011 (1), 258365, 2011 | 5 | 2011 |
| Drosophila D-idua Reduction Mimics Mucopolysaccharidosis Type I Disease-Related Phenotypes C De Filippis, B Napoli, L Rigon, G Guarato, R Bauer, R Tomanin, G Orso Cells 11 (1), 129, 2021 | 4 | 2021 |
| Early diagnosis of mucopolysaccharidoses in developing countries: A low cost and easy execution approach O Gabrielli, L Zampini, C Monachesi, RL Marchesiello, L Padella, ... Clin. Chim. Acta 468, 150-151, 2017 | 1 | 2017 |
| Clinical benefit of PD-L1 hematopoietic stem and progenitor cell gene therapy in an animal model of multiple sclerosis R Milazzo, S Spadini, G Santinon, Y Ciervo, M Kiyemba, L Rigon, ... HUMAN GENE THERAPY 33 (23-24), A15-A15, 2022 | | 2022 |
| Development of an ex vivo ene Therapy for Frontotemporal Dementia (FTD) Y Ciervo, A Toniolo, L Rigon, S Spadini, M Accardo, R Milazzo, A Biffi HUMAN GENE THERAPY 33 (23-24), A79-A79, 2022 | | 2022 |
| Development of an Ex Vivo Gene Therapy for Frontotemporal Dementia (FTD) Y Ciervo, L Rigon, S Spadini, M Accardo, R Milazzo, A Biffi MOLECULAR THERAPY 30 (4), 125-125, 2022 | | 2022 |
| Hematopoietic Stem and Progenitor Cell Gene Therapy Uniquely Benefits Multiple Sclerosis in the Animal Model S Spadini, R Milazzo, L Rigon, M Accardo, G Santinon, Y Ciervo, A Costa, ... MOLECULAR THERAPY 30 (4), 393-393, 2022 | | 2022 |